BACKGROUND: Prevalence of chronic hepatitis C virus (HCV) infection is high among incarcerated persons in the United States. New, short-duration, high-efficacy therapies may expand treatment eligibility in this population. OBJECTIVE: To assess the cost-effectiveness of sofosbuvir for HCV treatment in incarcerated populations. DESIGN: Markov model. DATA SOURCES: Published literature and expert opinion. TARGET POPULATION: Treatment-naive men with chronic, genotype 1 HCV monoinfection. TIME HORIZON: Lifetime. PERSPECTIVE: Societal. INTERVENTION: No treatment, 2-drug therapy (pegylated interferon and ribavirin), or 3-drug therapy with either boceprevir or sofosbuvir. For inmates with short remaining sentences (<1.5 years), only no treatment or sofosbuvir 3-drug therapy was feasible; for those with long sentences (≥1.5 years; mean, 10 years), all strategies were considered. After release, eligible persons could receive sofosbuvir 3-drug therapy. OUTCOME MEASURES: Discounted costs (in 2013 U.S. dollars), discounted quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. RESULTS OF BASE-CASE ANALYSIS: The strategies yielded 13.12, 13.57, 14.43, and 15.18 QALYs, respectively, for persons with long sentences. Sofosbuvir produced the largest absolute reductions in decompensated cirrhosis (16%) and hepatocellular carcinoma (9%), resulting in 2.1 additional QALYs at an added cost exceeding $54,000 compared with no treatment. For persons with short sentences, sofosbuvir cost $25,700 per QALY gained compared with no treatment; for those with long sentences, it dominated other treatments, costing $28,800 per QALY gained compared with no treatment. RESULTS OF SENSITIVITY ANALYSIS: High reinfection rates in prison attenuated cost-effectiveness for persons with long sentences. LIMITATIONS: Data on sofosbuvir's long-term effectiveness and price are limited. The analysis did not consider women, Hispanic persons, or patients co-infected with HIV or hepatitis B virus. CONCLUSION: Sofosbuvir-based treatment is cost-effective for incarcerated persons, but affordability is an important consideration. PRIMARY FUNDING SOURCE: National Institutes of Health.
BACKGROUND: Prevalence of chronic hepatitis C virus (HCV) infection is high among incarcerated persons in the United States. New, short-duration, high-efficacy therapies may expand treatment eligibility in this population. OBJECTIVE: To assess the cost-effectiveness of sofosbuvir for HCV treatment in incarcerated populations. DESIGN: Markov model. DATA SOURCES: Published literature and expert opinion. TARGET POPULATION: Treatment-naive men with chronic, genotype 1 HCV monoinfection. TIME HORIZON: Lifetime. PERSPECTIVE: Societal. INTERVENTION: No treatment, 2-drug therapy (pegylated interferon and ribavirin), or 3-drug therapy with either boceprevir or sofosbuvir. For inmates with short remaining sentences (<1.5 years), only no treatment or sofosbuvir 3-drug therapy was feasible; for those with long sentences (≥1.5 years; mean, 10 years), all strategies were considered. After release, eligible persons could receive sofosbuvir 3-drug therapy. OUTCOME MEASURES: Discounted costs (in 2013 U.S. dollars), discounted quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. RESULTS OF BASE-CASE ANALYSIS: The strategies yielded 13.12, 13.57, 14.43, and 15.18 QALYs, respectively, for persons with long sentences. Sofosbuvir produced the largest absolute reductions in decompensated cirrhosis (16%) and hepatocellular carcinoma (9%), resulting in 2.1 additional QALYs at an added cost exceeding $54,000 compared with no treatment. For persons with short sentences, sofosbuvir cost $25,700 per QALY gained compared with no treatment; for those with long sentences, it dominated other treatments, costing $28,800 per QALY gained compared with no treatment. RESULTS OF SENSITIVITY ANALYSIS: High reinfection rates in prison attenuated cost-effectiveness for persons with long sentences. LIMITATIONS: Data on sofosbuvir's long-term effectiveness and price are limited. The analysis did not consider women, Hispanic persons, or patients co-infected with HIV or hepatitis B virus. CONCLUSION:Sofosbuvir-based treatment is cost-effective for incarcerated persons, but affordability is an important consideration. PRIMARY FUNDING SOURCE: National Institutes of Health.
Authors: Alexander J Thompson; Andrew J Muir; Mark S Sulkowski; Dongliang Ge; Jacques Fellay; Kevin V Shianna; Thomas Urban; Nezam H Afdhal; Ira M Jacobson; Rafael Esteban; Fred Poordad; Eric J Lawitz; Jonathan McCone; Mitchell L Shiffman; Greg W Galler; William M Lee; Robert Reindollar; John W King; Paul Y Kwo; Reem H Ghalib; Bradley Freilich; Lisa M Nyberg; Stefan Zeuzem; Thierry Poynard; David M Vock; Karen S Pieper; Keyur Patel; Hans L Tillmann; Stephanie Noviello; Kenneth Koury; Lisa D Pedicone; Clifford A Brass; Janice K Albrecht; David B Goldstein; John G McHutchison Journal: Gastroenterology Date: 2010-04-24 Impact factor: 22.682
Authors: Hamish A Innes; Sharon J Hutchinson; Samuel Allen; Diptendu Bhattacharyya; Peter Bramley; Toby E S Delahooke; John F Dillon; Ewan Forrest; Andrew Fraser; Ruth Gillespie; David J Goldberg; Nicholas Kennedy; Scott McDonald; Allan McLeod; Peter R Mills; Judith Morris; Peter Hayes Journal: Hepatology Date: 2011-11 Impact factor: 17.425
Authors: Peter Ferenci; David Bernstein; Jacob Lalezari; Daniel Cohen; Yan Luo; Curtis Cooper; Edward Tam; Rui T Marinho; Naoky Tsai; Anders Nyberg; Terry D Box; Ziad Younes; Pedram Enayati; Sinikka Green; Yaacov Baruch; Bal Raj Bhandari; Florin Alexandru Caruntu; Thomas Sepe; Vladimir Chulanov; Ewa Janczewska; Giuliano Rizzardini; Judit Gervain; Ramon Planas; Christophe Moreno; Tarek Hassanein; Wangang Xie; Martin King; Thomas Podsadecki; K Rajender Reddy Journal: N Engl J Med Date: 2014-05-04 Impact factor: 91.245
Authors: Jacques G Baillargeon; Thomas P Giordano; Amy Jo Harzke; Gwen Baillargeon; Josiah D Rich; David P Paar Journal: Public Health Rep Date: 2010 Jan-Feb Impact factor: 2.792
Authors: Gary L Davis; John B Wong; John G McHutchison; Michael P Manns; Joann Harvey; Janice Albrecht Journal: Hepatology Date: 2003-09 Impact factor: 17.425
Authors: Eric Lawitz; Alessandra Mangia; David Wyles; Maribel Rodriguez-Torres; Tarek Hassanein; Stuart C Gordon; Michael Schultz; Mitchell N Davis; Zeid Kayali; K Rajender Reddy; Ira M Jacobson; Kris V Kowdley; Lisa Nyberg; G Mani Subramanian; Robert H Hyland; Sarah Arterburn; Deyuan Jiang; John McNally; Diana Brainard; William T Symonds; John G McHutchison; Aasim M Sheikh; Zobair Younossi; Edward J Gane Journal: N Engl J Med Date: 2013-04-23 Impact factor: 91.245
Authors: John T Nguyen; Josiah D Rich; Bradley W Brockmann; Fred Vohr; Anne Spaulding; Brian T Montague Journal: J Urban Health Date: 2015-08 Impact factor: 3.671
Authors: Anne C Spaulding; Akshay Sharma; Lauren C Messina; Maria Zlotorzynska; Lesley Miller; Ingrid A Binswanger Journal: Am J Public Health Date: 2015-03-19 Impact factor: 9.308
Authors: Lauren J Stockman; James Greer; Ryan Holzmacher; Beth Dittmann; Scott A Hoftiezer; Lori E Alsum; Audrey Prieve; Ryan P Westergaard; Sheila M Guilfoyle; James M Vergeront Journal: Public Health Rep Date: 2016 Jul-Aug Impact factor: 2.792
Authors: Ingrid A Binswanger; Patrick J Blatchford; Simon J Forsyth; Marc F Stern; Stuart A Kinner Journal: Public Health Rep Date: 2016 Jul-Aug Impact factor: 2.792
Authors: Tianhua He; Kan Li; Mark S Roberts; Anne C Spaulding; Turgay Ayer; John J Grefenstette; Jagpreet Chhatwal Journal: Ann Intern Med Date: 2015-11-24 Impact factor: 25.391
Authors: Josiah D Rich; Curt G Beckwith; Alexandria Macmadu; Brandon D L Marshall; Lauren Brinkley-Rubinstein; Joseph J Amon; M-J Milloy; Maximilian R F King; Jorge Sanchez; Lukoye Atwoli; Frederick L Altice Journal: Lancet Date: 2016-07-14 Impact factor: 79.321